orforglipron vs tirzepatide Orforglipron: The Oral Non-Peptide GLP-1 Agonist Foundayo Orforglipron vs Tirzepatide: How

Description

Clinical research on this drugs efficacy gives obesity experts reason for optimism

Se trata de frmacos totalmente nuevos para el control de la obesidad, con una gran eficacia y mnimos efectos adversos si se utilizan correctamente

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

Compared with LIR once a day, once weekly subcutaneous injection of DUL similarly lowers body weight: 2.90 kg (-3.61 kg for LIR) after 26 weeks of treatment (109)